Sarepta reports a third death of gene therapy in connection with the death of patients in connection with the death of patients

Another patient has died after he has received investigating therapy from Sarepta Therapeutics, the company confirmed Biospace.

In an email on Thursday evening, a spokesman said that death was taking place in June and was associated with a case of acute liver failure, which led to the same complications that led to a case Two previously reported deaths Combined with Sareptas Duchenne -Muskeldystrophy -Gen -Therapy -Evidys.

Sareptas is existing down 27% in retail in front of the market.

The newly unveiled death was that of a 51-year-old man who had participated in a phase-I-study on the muscular dystrophy (LGMD) of the limb girdel and was dealt with with Sareptas SRP-9004, such as Elefidys. Sarepta has before stuck These fatal liver complications at AAVS.

“While we do everything we can to ensure the safety of the patients, clinical studies have an inherent risk,” wrote the spokesman. “Our deepest condolences go to the family and all those who are involved in his care.”

Analysts found that the company did not report death in its Corporate update Early this week.

“We believe that the death of LGMD patient could hesitate to use the patient to use commercial eltidies and increase the distrust of the investor, since the company did not disclose the event with its call,” wrote William Blair in a note in a note early Friday morning.

The company announced on Wednesday that around 500 employees – over 36% of its workforce – would reduce the pipeline to achieve around 420 million US dollars of savings and to concentrate on its Sirna programs instead of gene therapies. The work on “Most genetic therapies in development for muscular dystrophy with limbs” are suspended. Sarepta shares rose around 20% After the announcement and analysts, business overhaul praised. BMO Capital Markets in a Wednesday note is called[positive] Turn into history. “

“The only risk we see is the death of a third patient patient,” said BMO.

This pipeline umbrella includes SRP-9004, for which the development together with most of the company's LGMD program, with the exception of SRP-9003, a further genetic therapy for LGMD, for which the company wants to submit an application to the FDA in the second half of this year.

When asked why Sarepta left out the news of the death of LGMD studies in his company update, the spokesman said that the company was transparent in terms of this development. “The event had already been communicated to adequate and timely supervisory authorities and investigators. We also tragically announced this tragic event of the community with which we have closely teamed up during the entire development process.”

The two deaths of the patients brought Sarepta to this at the beginning of this year Start a number of security initiatives For gene therapy. The biotech announced last month to organize an independent expert body in order to evaluate updated immunosuppressive regimes for patients. Sarepta also paused in Eledy's shipments for non -outpatient patients.

On Wednesday the company strengthened these efforts of Add a box warning Fighting the label for acute liver injury and acute liver failure.